





# Dr Reddys Laboratories Ltd

18 December 2024


## About company

Dr. Reddy's Laboratories Ltd is a multinational pharmaceutical company based in Hyderabad, India, founded in 1984. The company develops and manufactures a wide range of generic medicines, active pharmaceutical ingredients (APIs), and biosimilar, serving markets across the globe, including the U.S., Europe, and emerging markets. Dr. Reddy's is known for its focus on affordability and innovation in therapeutic areas such as oncology, gastroenterology, and pain management. It is listed on both the Bombay Stock Exchange (BSE) and the New York Stock Exchange (NYSE). The company is committed to improving access to affordable healthcare and investing in research for new drug development.

## Financials



<b>MARKET CAP</b>	RS 1,11,862 CR
<b>STOCK P/E</b>	20.1
<b>DIVIDEND YIELD</b>	0.60%
<b>ROCE</b>	26.5%
<b>ROE</b>	21.4%
<b>FACE VALUE</b>	5.00
<b>3 YEARS SALES GROWTH</b>	14%
<b>3 YEARS PROFIT GROWTH</b>	41%



**Our recommendation**

**OPTIONS INSIGHT: BUY DRREDDY 1270 CALL ABOVE 20 TARGET 30/40 STOPLOSS BELOW 10**

**Technical analysis**

Dr Reddy Laboratories share prices continue its bullish trend today after witnessing some profit booking yesterday. The price opened higher and sustained at the higher levels, indicating strong hold on upside with good amount of volumes. On technical front, the prices are trading above its 20 EMA level indicating a bullish momentum. Supertrend indicator is showing bullish trend as green zone is active in it (as shown in image below). The prices breaks recent high of 1273 with good volumes, so we are expecting it to reach 1290-1300 level, and on the downside 1258 can acts as the support level. Thus, we recommend DRREDDY 1270 CALL option.



## **Disclaimer**

I, Ruchi Nahar, SEBI Registered Research Analyst (INH000014544) comply with the qualification and certification requirements under SEBI (Research Analyst) Regulations, 2014. I have qualified CA, CS and MBA, has over 11 years of experience in MNCs, culminating as Head of Finance. I now leverage my expertise to guide stock market investors with strategic insights. All of the views expressed in research reports and recommendations issued by me reflect my personal views about the subject company or companies at the given point of time and I do not receive/accept any kind of compensation, directly or indirectly related to specific recommendations or views expressed in reports issued by me. I/my relatives do not at any point of time of issuing the reports have any material conflict of interest in the subject company neither I was/am/will be engaged in market making activity for the subject company. The investments discussed or views expressed in reports and recommendations issued by me may not be suitable for all investors. The user assumes the entire risk of any use made of this information. I nor any person connected with my report, accepts any liability arising from the use of research document. The recipients of research document should rely on their own investigations and should consult their own financial advisors to determine merit and risks of such investments based on their own risk appetite. Price and value of the investments referred to in this material may go up or down. Past performance is not a guide for future performance. Certain transactions including those involving futures, options and other derivatives as well as non-investment grade securities involve substantial risk and are not suitable for all investors. Reports and recommendations based on technical analysis centres on studying charts of a stock's price movement and trading volume, as opposed to focusing on a company's fundamentals and as such, may not match with a report on a company's fundamentals. Opinions expressed in research reports & recommendations will be based on the current opinions as of the date appearing in research report & recommendations. While I endeavour to update on a reasonable basis the information discussed in research reports, there may be regulatory, compliance, or other reasons that prevent me from doing so. Prospective investors and others are cautioned that any forward-looking statements are not predictions and may be subject to change without notice. So far as reports include current or historic information, it is believed to be reliable, although its accuracy and completeness cannot be guaranteed. Investment in securities market is subject to market risks. Read all the related documents carefully before investing. Registration granted by SEBI, and certification from NISM in no way guarantee performance of the intermediary or provide any assurance of returns to investors.

18 December 2024

